Esquemas terapêuticos com bedaquilina e tuberculose multirresistente: revisão sistemática e meta-análise

Hatami, Hossein; Sotgiu, Giovanni; Bostanghadiri, Narjess; Abadi, Sahel Shafiee Dolat; Mesgarpour, Bita; Goudarzi, Hossein; Migliori, Giovanni Battista; Nasiri, Mohammad Javad

Hossein Hatami

. Department of Public Health, School of Public Health and Safety; Environmental and Occupational Hazards Control Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

https://orcid.org/0000-0002-1448-3598

Giovanni Sotgiu

. Unità di Epidemiologia Clinica e Statistica Medica, Dipartimento di Scienze Mediche Chirurgiche e Sperimentali, Università degli Studi di Sassari, Sassari, Italia.

https://orcid.org/0000-0002-1600-4474

Narjess Bostanghadiri

. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

https://orcid.org/0000-0002-7343-5289

Sahel Shafiee Dolat Abadi

. Department of Public and International Affairs, National Institute for Medical Research Development - NIMAD - Tehran, Iran.

https://orcid.org/0000-0003-4231-844X

Bita Mesgarpour

. Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

https://orcid.org/0000-0002-4004-8493

Hossein Goudarzi

. Department of Public and International Affairs, National Institute for Medical Research Development - NIMAD - Tehran, Iran.

https://orcid.org/0000-0001-8965-8690

Giovanni Battista Migliori

. Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italia.

https://orcid.org/0000-0002-2597-574X

Mohammad Javad Nasiri

. Department of Public and International Affairs, National Institute for Medical Research Development - NIMAD - Tehran, Iran.

https://orcid.org/0000-0002-3279-0671

Endereço para correspondência:
Mohammad Javad Nasiri. Shahid Beheshti University of Medical Sciences, Arabi Avenue, Daneshjoo Blvd, Velenjak, 19839-63113, Tehran, Iran. Tel.: 98 21 22 43 25 56. E-mail: mj.nasiri@hotmail.com ou Giovanni Battista Migliori. Istituti Clinici Scientifici Maugeri - IRCCS, Via Roncaccio 16, 21049, Tradate, Italia. Tel.: 39 0331 829404. E-mail: gbmigliori@fsm.it

CONTRIBUIÇÕES DOS AUTORES

Todos os autores participaram da redação e revisão do manuscrito, bem como da aprovação da versão final.

CONFLITO DE INTERESSE

Nenhum conflito declarado.

Autor	Ano	País	Tipo de estudo	Média/ mediana da idade	HIV+, n (%)	Tratamento prévio de tuberculose	Doença tuberculosa	N. de pacientes tratados com BDQ	Outros medicamentos incluídos no esquema	Duração do tratamento (meses)	Desfechos
Autor	Ano	País	Tipo de estudo	Média/ mediana da idade	HIV+, n (%)	Tratamento prévio de tuberculose	Doença tuberculosa	N. de pacientes tratados com BDQ	Outros medicamentos incluídos no esquema	Duração do tratamento (meses)	Sucesso do tratamento	Falha do tratamento	Óbito
Koirala et al.¹¹11 Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403-412. https://doi.org/10.1016/j.pulmoe.2021.02.006 https://doi.org/10.1016/j.pulmoe.2021.02...	2021	Multicêntrico	PC	39	27 (5,7)	329	MDR/XDR	383	Esquema recomendado pela OMS	6	284	11	25
Kwon et al.¹⁶16 Kwon YS, Jeon D, Kang H, Yim JJ, Shim TS. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea. Eur Respir J. 2021;57(3):2003026. https://doi.org/10.1183/13993003.03026-2020 https://doi.org/10.1183/13993003.03026-2...	2021	Coreia do Sul	RC	49	0	19	Pré-XDR/XDR	28	DLM+LZD+CFZ+MEM/CLV+CYC	6	23	2	1
Shi et al.¹⁷17 Shi L, Gao J, Gao M, Deng P, Chen S, He M, et al. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. Infect Dis Ther. 2021;10(1):457-470. https://doi.org/10.1007/s40121-021-00396-9 https://doi.org/10.1007/s40121-021-00396...	2021	China	RC	49.8	N/R	186	MDR	72	FLQs+LZD+CFZ+CYC	6	197	4	0
							pré-XDR	78
							XDR	64
Gao et al.¹⁸18 Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597-602. https://doi.org/10.1016/j.cmi.2020.06.004 https://doi.org/10.1016/j.cmi.2020.06.00...	2021	China	RC	40	1 (0,6)	168	MDR	39	FLQs+LZD+CFZ+CYC	6	151	23	3
							pré-XDR	56
							XDR	82
Barvaliya et al.¹⁹19 Barvaliya SV, Desai MK, Panchal JR, Solanki RN. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Indian J Tuberc. 2020;67(2):222-230. https://doi.org/10.1016/j.ijtb.2020.03.002 https://doi.org/10.1016/j.ijtb.2020.03.0...	2020	Índia	PC	31	N/R	110	Pré-XDR	87	FLQs+LZD+CFZ	5,5	102	10	14
	2020	Índia	PC	31	N/R	110	XDR	40	FLQs+LZD+CFZ	5,5	102	10	14
Kashongwe et al.²⁰20 Kashongwe IM, Mawete F, Mbulula L, Nsuela DJ, Losenga L, Anshambi N, et al. Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study. PLoS One. 2020;15(8):e0236264. https://doi.org/10.1371/journal.pone.0236264 https://doi.org/10.1371/journal.pone.023...	2020	Congo	RC	32.4	3 (9,4)	23	Pré-XDR	29	FLQs+LZD+CFZ+CYC	20	17	0	15
	2020	Congo	RC	32.4	3 (9,4)	23	XDR	3	FLQs+LZD+CFZ+CYC	20	17	0	15
Das et al.²¹21 Das M, Mamnoon F, Mansoor H, Meneguim AC, Singh P, Shah I, et al. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India. Int J Tuberc Lung Dis. 2020;24(12):1265-1271. https://doi.org/10.5588/ijtld.20.0165 https://doi.org/10.5588/ijtld.20.0165...	2020	Índia	RC	Crianças/adolescentes	0	N/R	Pré-XDR/XDR	13	DLM+ LZD+CFZ	22	12 ou 13	N/R	N/R
Lee et al.²²22 Lee HH, Jo KW, Yim JJ, Jeon D, Kang H, Shim TS. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid. Int J Infect Dis. 2020;98:478-485. https://doi.org/10.1016/j.ijid.2020.07.001 https://doi.org/10.1016/j.ijid.2020.07.0...	2020	Coreia do Sul	RC	49,8	1 (1,4)	49	MDR	13	DLM+FLQs+ LZD+CFZ+CYC	5,5	42	1	4
							Pré-XDR	41
							XDR	20
Kim et al.²³23 Kim JH, Kwon OJ, Kim YS, Park MS, Hwang S, Shim TS. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation. Respir Investig. 2020;58(1):45-51. https://doi.org/10.1016/j.resinv.2019.08.004 https://doi.org/10.1016/j.resinv.2019.08...	2020	Coreia do Sul	RC	33	9 (3,5)	254	MDR	159	AMGs+FLQs+LZD+CYC	6	139/225	35/225	15/225
							Pré-XDR	51
							XDR	44
Mase et al.²⁴24 Mase S, Chorba T, Parks S, Belanger A, Dworkin F, Seaworth B, et al. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clin Infect Dis. 2020;71(4):1010-1016. https://doi.org/10.1093/cid/ciz914 https://doi.org/10.1093/cid/ciz914...	2020	EUA	RC	43,5	1 (7)	5	MDR	7	Esquema recomendado pela OMS	5,5	12	N/R	1
							Pré-XDR	4
							XDR	3
Olayanju et al.²⁵25 Olayanju O, Esmail A, Limberis J, Dheda K. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J. 2020;55(1):1901181. https://doi.org/10.1183/13993003.01181-2019 https://doi.org/10.1183/13993003.01181-2...	2020	África do Sul	PC	33	42 (51)	40	MDR	5	AMGs+FLQs+LZD+CFZ+TRD	6	52	N/R	N/R
							Pré-XDR	10
							XDR	67
				34	22 (55)	29	MDR	6	DLM+AMGs+FLQs+LZD+CFZ+TRD	6	27	N/R	N/R
							Pré-XDR	15
							XDR	19
Salhotra et al.²⁶26 Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. Indian J Tuberc. 2020;67(1):29-37. https://doi.org/10.1016/j.ijtb.2019.10.002 https://doi.org/10.1016/j.ijtb.2019.10.0...	2020	Índia	PC	Variação: 18-50	8 (1,3)	600	MDR	524	AMGs+FLQs+CFZ	6	513	N/R	73
	2020	Índia	PC	Variação: 18-50	8 (1,3)	600	XDR	96	AMGs+FLQs+CFZ	6	513	N/R	73
Chesov et al.²⁷27 Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reimann M, et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J. 2021;57(6):2002544. https://doi.org/10.1183/13993003.02544-2020 https://doi.org/10.1183/13993003.02544-2...	2020	Moldávia	RC	37	17 (14.9)	58	MDR	114	AMGs+FLQs+CYC+PZA	6	63	31	10
Kang et al.²⁸28 Kang H, Jo KW, Jeon D, Yim JJ, Shim TS. Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea. Respir Med. 2020;167:105956. https://doi.org/10.1016/j.rmed.2020.105956 https://doi.org/10.1016/j.rmed.2020.1059...	2020	Coreia do Sul	RC	51,7	0	55	MDR	43	AMGs+FLQs+LZD+CYC	6	86	1	13
							Pré-XDR	47
							XDR	17
				47,7	1 (1,5)	47	MDR	8	DLM+AMGs+FLQs+LZD+CYC	6	58	3	3
							Pré-XDR	37
							XDR	22
Sarin et al.²⁹29 Sarin R, Vohra V, Singla N, Singla R, Puri MM, Munjal SK, et al. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Indian J Tuberc. 2019;66(1):184-188. https://doi.org/10.1016/j.ijtb.2019.02.006 https://doi.org/10.1016/j.ijtb.2019.02.0...	2019	Índia	PC	Variação: 21-33	0	N/R	MDR/Pré-XDR/XDR	42	DLM+ FLQs+LZD+CFZ+IMP	6	25	N/R	10
Kempker et al.³⁰30 Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens. Clin Infect Dis. 2020;71(9):2336-2344. https://doi.org/10.1093/cid/ciz1107 https://doi.org/10.1093/cid/ciz1107...	2019	EUA	PC	37,3	2 (3)	8	MDR/XDR	64	FLQs+LZD+CFZ+CYC+IMP	5,5	42	1	0
Taune et al.³¹31 Taune M, Ustero P, Hiashiri S, Huang K, Aia P, Morris L, et al. Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. Public Health Action. 2019;9(Suppl 1):S73-S79. https://doi.org/10.5588/pha.18.0071 https://doi.org/10.5588/pha.18.0071...	2019	Nova Guiné	RC	39	1 (1,3)	33	MDR	55	AMGs+FLQs+LZD+CFZ+CYC+PZA	6	72	N/R	5
							Pré-XDR	10
							XDR	12
Ferlazzo et al.³²32 Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018;18(5):536-544. https://doi.org/10.1016/S1473-3099(18)30100-2 https://doi.org/10.1016/S1473-3099(18)30...	2018	Armênia, Índia, África do Sul	RC	32,5	11 (39)	4	MDR	2	DLM+ FLQs+LZD+CFZ+IMP	6	22	N/R	1
							Pré-XDR	12
							XDR	14
Hewison et al.³³33 Hewison C, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, et al. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. Int J Tuberc Lung Dis. 2018;22(7):766-772. https://doi.org/10.5588/ijtld.17.0840 https://doi.org/10.5588/ijtld.17.0840...	2018	Armênia, Geórgia	RC	40,5	4 (4,8)	N/R	MDR	6	FLQs+LZD+CFZ+IMP	6	48	6	10
							Pré-XDR	36
							XDR	40
Ndjeka et al.³⁴34 Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018;52(6):1801528. https://doi.org/10.1183/13993003.01528-2018 https://doi.org/10.1183/13993003.01528-2...	2018	África do Sul	PC	34	134 (67)	N/R	Pré-XDR	122	FLQs+LZD+CFZ	6	146	9	25
	2018	África do Sul	PC	34	134 (67)	N/R	XDR	78	FLQs+LZD+CFZ	6	146	9	25
Zhao et al.³⁵35 Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis. 2019;68(9):1522-1529. https://doi.org/10.1093/cid/ciy727 https://doi.org/10.1093/cid/ciy727...	2018	África do Sul	RC	Variação: 35-49	110 (68)	N/R	MDR	162	FLQs+PZA+ETH+INHa+ETM+TRD	6	111/146	7/119	11/145
Kim et al.³⁶36 Kim CT, Kim TO, Shin HJ, Ko YC, Hun Choe Y, Kim HR, et al. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Eur Respir J. 2018;51(3):1702467. https://doi.org/10.1183/13993003.02467-2017 https://doi.org/10.1183/13993003.02467-2...	2018	Coreia do Sul	RC	52	N/R	N/R	MDR/Pré-XDR/XDR	39	FLQs+LZD+CFZ	5,6	24	N/R	N/R
Achar et al.³⁷37 Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2017;23(10):1711-1713. https://doi.org/10.3201/eid2310.170303 https://doi.org/10.3201/eid2310.170303...	2017	África do Sul, Tajiquistão, Uzbequistão, Bielorrússia	PC	Crianças/adolescentes	0	N/R	Pré-XDR/XDR	23	FLQs+LZD+CFZ+IMP	6	23	0	0
Guglielmetti et al.³⁸38 Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601799. https://doi.org/10.1183/13993003.01799-2016 https://doi.org/10.1183/13993003.01799-2...	2017	França	RC	38	2 (4,4)	34	MDR/Pré-XDR/XDR	45	AMGs+FLQs+LZD+CFZ+CYC+PZA+ETH+ETM	6	36	1	3
Borisov et al.¹⁰10 Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. https://doi.org/10.1183/13993003.00387-2017 https://doi.org/10.1183/13993003.00387-2...	2017	Multicêntrico	RC	35	94 (22,1)	334	MDR	233	AMGs+FLQs+LZD+CFZ+IMP	5,5	176/247	18/247	33/247
	2017	Multicêntrico	RC	35	94 (22,1)	334	XDR	195	AMGs+FLQs+LZD+CFZ+IMP	5,5	176/247	18/247	33/247
Conradie et al.³⁹39 Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893-902. https://doi.org/10.1056/NEJMoa1901814 https://doi.org/10.1056/NEJMoa1901814...	2020	África do Sul	EC	35	56 (51)	N/R	MDR	38	LZD+PMD	6	98	2	7
	2020	África do Sul	EC	35	56 (51)	N/R	XDR	71	LZD+PMD	6	98	2	7
Tweed et al.⁴⁰40 Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019;7(12):1048-1058. https://doi.org/10.1016/S2213-2600(19)30366-2 https://doi.org/10.1016/S2213-2600(19)30...	2019	África do Sul, Tanzânia, Uganda	EC	34	25 (42)	N/R	RR	60	FLQs+PZA+PMD	6	58	N/R	0
Pym et al.⁴¹41 Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564-574. https://doi.org/10.1183/13993003.00724-2015 https://doi.org/10.1183/13993003.00724-2...	2016	Multicêntrico	EC	32	8 (4)	177	MDR	124	AMGs+FLQs+ CYC+PZA+ETH	6	163	N/R	N/R
							Pré-XDR	44
							XDR	37
Diacon et al.⁴²42 Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-732. https://doi.org/10.1056/NEJMoa1313865 https://doi.org/10.1056/NEJMoa1313865...	2014	Multicêntrico	EC	32	5 (8)	N/R	MDR	66	AMGs+FLQs+ CYC+PZA+ETH	6	52	N/R	N/R

Autor	1	2	3	4	5	6	7	8	9	10	11
Koirala et al.¹¹11 Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403-412. https://doi.org/10.1016/j.pulmoe.2021.02.006 https://doi.org/10.1016/j.pulmoe.2021.02...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Kwon et al.¹⁶16 Kwon YS, Jeon D, Kang H, Yim JJ, Shim TS. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea. Eur Respir J. 2021;57(3):2003026. https://doi.org/10.1183/13993003.03026-2020 https://doi.org/10.1183/13993003.03026-2...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Shi et al.¹⁷17 Shi L, Gao J, Gao M, Deng P, Chen S, He M, et al. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. Infect Dis Ther. 2021;10(1):457-470. https://doi.org/10.1007/s40121-021-00396-9 https://doi.org/10.1007/s40121-021-00396...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Gao et al.¹⁸18 Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597-602. https://doi.org/10.1016/j.cmi.2020.06.004 https://doi.org/10.1016/j.cmi.2020.06.00...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Barvaliya et al.¹⁹19 Barvaliya SV, Desai MK, Panchal JR, Solanki RN. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Indian J Tuberc. 2020;67(2):222-230. https://doi.org/10.1016/j.ijtb.2020.03.002 https://doi.org/10.1016/j.ijtb.2020.03.0...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Kashongwe et al.²⁰20 Kashongwe IM, Mawete F, Mbulula L, Nsuela DJ, Losenga L, Anshambi N, et al. Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study. PLoS One. 2020;15(8):e0236264. https://doi.org/10.1371/journal.pone.0236264 https://doi.org/10.1371/journal.pone.023...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Das et al.²¹21 Das M, Mamnoon F, Mansoor H, Meneguim AC, Singh P, Shah I, et al. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India. Int J Tuberc Lung Dis. 2020;24(12):1265-1271. https://doi.org/10.5588/ijtld.20.0165 https://doi.org/10.5588/ijtld.20.0165...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Lee et al.²²22 Lee HH, Jo KW, Yim JJ, Jeon D, Kang H, Shim TS. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid. Int J Infect Dis. 2020;98:478-485. https://doi.org/10.1016/j.ijid.2020.07.001 https://doi.org/10.1016/j.ijid.2020.07.0...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Kim et al.²³23 Kim JH, Kwon OJ, Kim YS, Park MS, Hwang S, Shim TS. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation. Respir Investig. 2020;58(1):45-51. https://doi.org/10.1016/j.resinv.2019.08.004 https://doi.org/10.1016/j.resinv.2019.08...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Mase et al.²⁴24 Mase S, Chorba T, Parks S, Belanger A, Dworkin F, Seaworth B, et al. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clin Infect Dis. 2020;71(4):1010-1016. https://doi.org/10.1093/cid/ciz914 https://doi.org/10.1093/cid/ciz914...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Olayanju et al.²⁵25 Olayanju O, Esmail A, Limberis J, Dheda K. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J. 2020;55(1):1901181. https://doi.org/10.1183/13993003.01181-2019 https://doi.org/10.1183/13993003.01181-2...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Salhotra et al.²⁶26 Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. Indian J Tuberc. 2020;67(1):29-37. https://doi.org/10.1016/j.ijtb.2019.10.002 https://doi.org/10.1016/j.ijtb.2019.10.0...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Chesov et al.²⁷27 Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reimann M, et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J. 2021;57(6):2002544. https://doi.org/10.1183/13993003.02544-2020 https://doi.org/10.1183/13993003.02544-2...	Sim	Sim	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Kang et al.²⁸28 Kang H, Jo KW, Jeon D, Yim JJ, Shim TS. Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea. Respir Med. 2020;167:105956. https://doi.org/10.1016/j.rmed.2020.105956 https://doi.org/10.1016/j.rmed.2020.1059...	Sim	Sim	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Sarin et al.²⁹29 Sarin R, Vohra V, Singla N, Singla R, Puri MM, Munjal SK, et al. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Indian J Tuberc. 2019;66(1):184-188. https://doi.org/10.1016/j.ijtb.2019.02.006 https://doi.org/10.1016/j.ijtb.2019.02.0...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Kempker et al.³⁰30 Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens. Clin Infect Dis. 2020;71(9):2336-2344. https://doi.org/10.1093/cid/ciz1107 https://doi.org/10.1093/cid/ciz1107...	Sim	Sim	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Taune et al.³¹31 Taune M, Ustero P, Hiashiri S, Huang K, Aia P, Morris L, et al. Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. Public Health Action. 2019;9(Suppl 1):S73-S79. https://doi.org/10.5588/pha.18.0071 https://doi.org/10.5588/pha.18.0071...	Sim	Sim	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Ferlazzo et al.³²32 Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018;18(5):536-544. https://doi.org/10.1016/S1473-3099(18)30100-2 https://doi.org/10.1016/S1473-3099(18)30...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Hewison et al.³³33 Hewison C, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, et al. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. Int J Tuberc Lung Dis. 2018;22(7):766-772. https://doi.org/10.5588/ijtld.17.0840 https://doi.org/10.5588/ijtld.17.0840...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Ndjeka et al.³⁴34 Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018;52(6):1801528. https://doi.org/10.1183/13993003.01528-2018 https://doi.org/10.1183/13993003.01528-2...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Zhao et al.³⁵35 Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis. 2019;68(9):1522-1529. https://doi.org/10.1093/cid/ciy727 https://doi.org/10.1093/cid/ciy727...	Sim	Sim	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Kim et al.³⁶36 Kim CT, Kim TO, Shin HJ, Ko YC, Hun Choe Y, Kim HR, et al. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Eur Respir J. 2018;51(3):1702467. https://doi.org/10.1183/13993003.02467-2017 https://doi.org/10.1183/13993003.02467-2...	Sim	Sim	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Achar et al.³⁷37 Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2017;23(10):1711-1713. https://doi.org/10.3201/eid2310.170303 https://doi.org/10.3201/eid2310.170303...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Guglielmetti et al.³⁸38 Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601799. https://doi.org/10.1183/13993003.01799-2016 https://doi.org/10.1183/13993003.01799-2...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Borisov et al.¹⁰10 Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. https://doi.org/10.1183/13993003.00387-2017 https://doi.org/10.1183/13993003.00387-2...	N/A	N/A	Sim	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim

Autor	1	2	3	4	5	6	7	8	9	10	11	12	13
Conradie et al.³⁹39 Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893-902. https://doi.org/10.1056/NEJMoa1901814 https://doi.org/10.1056/NEJMoa1901814...	Não	N/A	N/A	Não	Não	Não	Não	Sim	Sim	N/A	Sim	Sim	Não
Tweed et al.⁴⁰40 Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019;7(12):1048-1058. https://doi.org/10.1016/S2213-2600(19)30366-2 https://doi.org/10.1016/S2213-2600(19)30...	Sim	Não	Sim	Não	Não	Não	Não	Sim	Sim	Sim	Sim	Sim	Sim
Pym et al.⁴¹41 Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564-574. https://doi.org/10.1183/13993003.00724-2015 https://doi.org/10.1183/13993003.00724-2...	Não	Não	N/A	Não	Não	Não	Não	Sim	Sim	N/A	Sim	Sim	Não
Diacon et al.⁴²42 Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-732. https://doi.org/10.1056/NEJMoa1313865 https://doi.org/10.1056/NEJMoa1313865...	Sim	Sim	Sim	Sim	Sim	Sim	Não	Sim	Sim	Sim	Sim	Sim	Sim

Autor	Prolongamento do QTc	Doença hepática/ Enzimas hepáticas elevadas	Insuficiência renal/ Aumento da creatinina	Neuropatia óptica/ Visão turva	Ototoxicidade/Perda auditiva	Distúrbios hematológicos (anemia, trombocitopenia, eosinofilia)	Sintomas gastrointestinais (diarreia, vômito, náusea, dor abdominal)	Neuropatia periférica	Distúrbio eletrolítico	Artralgia	Transtorno psiquiátrico	Sintomas dermatológicos
Kwon et al.¹⁶16 Kwon YS, Jeon D, Kang H, Yim JJ, Shim TS. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea. Eur Respir J. 2021;57(3):2003026. https://doi.org/10.1183/13993003.03026-2020 https://doi.org/10.1183/13993003.03026-2...	17	NR	N/R	N/R	N/R	N/R	1	N/R	N/R	N/R	N/R	N/R
Shi et al.¹⁷17 Shi L, Gao J, Gao M, Deng P, Chen S, He M, et al. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. Infect Dis Ther. 2021;10(1):457-470. https://doi.org/10.1007/s40121-021-00396-9 https://doi.org/10.1007/s40121-021-00396...	85	59	21	13	10	24	15	16	5	3	9	2
Gao et al.¹⁸18 Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597-602. https://doi.org/10.1016/j.cmi.2020.06.004 https://doi.org/10.1016/j.cmi.2020.06.00...	39	35	9	2	6	15	11	8	11	2	6	N/R
Barvaliya et al.¹⁹19 Barvaliya SV, Desai MK, Panchal JR, Solanki RN. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Indian J Tuberc. 2020;67(2):222-230. https://doi.org/10.1016/j.ijtb.2020.03.002 https://doi.org/10.1016/j.ijtb.2020.03.0...	11	6	N/R	5	4	N/R	33	4	N/R	9	4	18
Kashongwe et al.²⁰20 Kashongwe IM, Mawete F, Mbulula L, Nsuela DJ, Losenga L, Anshambi N, et al. Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study. PLoS One. 2020;15(8):e0236264. https://doi.org/10.1371/journal.pone.0236264 https://doi.org/10.1371/journal.pone.023...	3	1	N/R	2	5	14	15	15	N/R	N/R	N/R	15
Das et al.²¹21 Das M, Mamnoon F, Mansoor H, Meneguim AC, Singh P, Shah I, et al. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India. Int J Tuberc Lung Dis. 2020;24(12):1265-1271. https://doi.org/10.5588/ijtld.20.0165 https://doi.org/10.5588/ijtld.20.0165...	1	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Lee et al.²²22 Lee HH, Jo KW, Yim JJ, Jeon D, Kang H, Shim TS. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid. Int J Infect Dis. 2020;98:478-485. https://doi.org/10.1016/j.ijid.2020.07.001 https://doi.org/10.1016/j.ijid.2020.07.0...	23	N/R	1	N/R	N/R	N/R	4	N/R	N/R	N/R	N/R	N/R
Kim et al.²³23 Kim JH, Kwon OJ, Kim YS, Park MS, Hwang S, Shim TS. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation. Respir Investig. 2020;58(1):45-51. https://doi.org/10.1016/j.resinv.2019.08.004 https://doi.org/10.1016/j.resinv.2019.08...	7	28	N/R	N/R	N/R	N/R	32	N/R	N/R	34	N/R	8
Mase et al.²⁴24 Mase S, Chorba T, Parks S, Belanger A, Dworkin F, Seaworth B, et al. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clin Infect Dis. 2020;71(4):1010-1016. https://doi.org/10.1093/cid/ciz914 https://doi.org/10.1093/cid/ciz914...	6	N/R	N/R	N/R	2	2	4	7	4	N/R	3	3
Olayanju et al.²⁵25 Olayanju O, Esmail A, Limberis J, Dheda K. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J. 2020;55(1):1901181. https://doi.org/10.1183/13993003.01181-2019 https://doi.org/10.1183/13993003.01181-2...	12	36	N/R	8	59	43	30	30	N/R	20	9	N/R
Salhotra et al.²⁶26 Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. Indian J Tuberc. 2020;67(1):29-37. https://doi.org/10.1016/j.ijtb.2019.10.002 https://doi.org/10.1016/j.ijtb.2019.10.0...	14	13	4	N/R	8	22	35	26	7	N/R	15	1
Kempker et al.³⁰30 Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens. Clin Infect Dis. 2020;71(9):2336-2344. https://doi.org/10.1093/cid/ciz1107 https://doi.org/10.1093/cid/ciz1107...	1	1	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Taune et al.³¹31 Taune M, Ustero P, Hiashiri S, Huang K, Aia P, Morris L, et al. Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. Public Health Action. 2019;9(Suppl 1):S73-S79. https://doi.org/10.5588/pha.18.0071 https://doi.org/10.5588/pha.18.0071...	1	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Ferlazzo et al.³²32 Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018;18(5):536-544. https://doi.org/10.1016/S1473-3099(18)30100-2 https://doi.org/10.1016/S1473-3099(18)30...	4	N/R	1	N/R	N/R	N/R	1	1	N/R	N/R	2	N/R
Hewison et al.³³33 Hewison C, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, et al. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. Int J Tuberc Lung Dis. 2018;22(7):766-772. https://doi.org/10.5588/ijtld.17.0840 https://doi.org/10.5588/ijtld.17.0840...	12	27	5	1	9	3	34	21	N/R	N/R	N/R	6
Ndjeka et al.³⁴34 Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018;52(6):1801528. https://doi.org/10.1183/13993003.01528-2018 https://doi.org/10.1183/13993003.01528-2...	10	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Achar et al.³⁷37 Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2017;23(10):1711-1713. https://doi.org/10.3201/eid2310.170303 https://doi.org/10.3201/eid2310.170303...	0	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Guglielmetti et al.³⁸38 Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601799. https://doi.org/10.1183/13993003.01799-2016 https://doi.org/10.1183/13993003.01799-2...	13	17	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Borisov et al.¹⁰10 Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. https://doi.org/10.1183/13993003.00387-2017 https://doi.org/10.1183/13993003.00387-2...	24/248	N/R	47/413	10/413	N/R	86/412	130/413	96/412	N/R	84/412	29/413	63/412
Conradie et al.³⁹39 Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893-902. https://doi.org/10.1056/NEJMoa1901814 https://doi.org/10.1056/NEJMoa1901814...	0	17	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Tweed et al.⁴⁰40 Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019;7(12):1048-1058. https://doi.org/10.1016/S2213-2600(19)30366-2 https://doi.org/10.1016/S2213-2600(19)30...	0	4	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R	N/R
Efeito aleatório combinado	10,4 (6,2-17,0)	11,7 (6,5-20,0)	4,6 (2,3-8,9)	3,8 (2,4-6,1)	7,8 (2,3-23,0)	13,6 (7,1-24,7)	15,3 (7,5-24,1)	13,8 (9,4-24,0)	4,7 (1,3-15,2)	8,1 (4,3-14,6)	5,1 (3,3-7,9)	7,5 (3,3-16,0)
Heterogeneidade, I² (%)	92%	93%	85%	50%	96%	94%	94%	94%	89%	89%	68%	91%
Teste de Begg, p	0,46	0,21	0,13	0,54	0,90	0,71	0,90	0,72	0,65	0,00	0,82	0,22

Subgrupo	N. de estudos	N. de pacientes	Taxa de sucesso do tratamento (%) (IC95%)	Heterogeneidade I² (%)	Teste de Begg valor de p
Esquema terapêutico: Esquema com BDQ Esquema com BDQ+DLM	22 7	3.287 292	74,5 (67,6-80,3) 73,9 (62,1-83,0)	91 72	0,61 0,03
Tipo de estudo: Estudo observacional Estudo experimental	25 4	3.536 440	74,7 (69,8-79,0) 86,1 (76,8-92)	86 75	0,18 0,08

[1] Endereço para correspondência:
Mohammad Javad Nasiri. Shahid Beheshti University of Medical Sciences, Arabi Avenue, Daneshjoo Blvd, Velenjak, 19839-63113, Tehran, Iran. Tel.: 98 21 22 43 25 56. E-mail: mj.nasiri@hotmail.com ou Giovanni Battista Migliori. Istituti Clinici Scientifici Maugeri - IRCCS, Via Roncaccio 16, 21049, Tradate, Italia. Tel.: 39 0331 829404. E-mail: gbmigliori@fsm.it

Brasil

Brasil

Esquemas terapêuticos com bedaquilina e tuberculose multirresistente: revisão sistemática e meta-análise

RESUMO

Objetivo:

Métodos:

Resultados:

Conclusões: